How does it work?

By targeting both receptors, Tirzepatide enhances insulin secretion and reduces glucagon secretion in a glucose-dependent manner, contributing to improved glycemic control. In addition to its glucose-lowering effects, tirzepatide has been associated with significant weight loss in clinical trials. This can be particularly beneficial for individuals with type 2 diabetes, as weight management is a crucial aspect of overall diabetes care. Like other newer diabetes medications, tirzepatide has undergone cardiovascular outcomes trials. These trials assess the impact of the medication on cardiovascular events, providing valuable information on the safety and potential cardiovascular benefits of the drug.

Tirzepatide is a synthetic peptide that acts as an agonist for both the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors. It is a gastric inhibitory polypeptide mimic and has 39 amino acids. Functionally, it causes the pancreas to release more insulin, which lowers blood sugar levels. Adiponectin concentrations are similarly raised by tirzepatide. Its dual agonism ability decreases hunger and significantly lowers hyperglycemia compared to GLP-1 agonist drugs used alone